C-Path’s Ramona Walls Promoted to Executive Director of Data Science TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) has named Ramona L. Walls, Ph.D., as Executive Director of Da
C-Path and Sturge-Weber Foundation Announce Data Sharing Agreement to Support Treatment Development for Sturge-Weber Syndrome TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) and the Sturge-Weber Foundation today announced a joint colla
C-Path’s Transplant Therapeutics Consortium Receives EMA Draft Qualification Opinion for iBox Scoring System The draft EMA qualification opinion is available for public consultation until November 17, 2022 Secondary endpoint prognostic for
October 1, 2022 Perspectives on Drug Development in Early ADPKD The Critical Path Institute’s Polycystic Disease Outcomes Consortium, including key stakeholders (patients, medical experts
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Alpha-1 Antitrypsin Deficiency TUCSON, Ariz., Oct. 6, 2022 — Critical Path Institute (C-Path) today announced that it has recently launched a pre-consortium co
October 1, 2022 Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease Autosomal recessive polycystic kidney disease (ARPKD) is a rare hepatorenal fibrocystic disease that often presents prenatally
October 18, 2022 View Now | INC 2022 Scientific Meeting We’re excited to see you at the International Neonatal Consortium 2022 Scientific Meeting this fall. #INC2022 will feature
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
October 25, 2022-October 27, 2022 2022 C-Path Neuroscience Annual Meeting C-Path’s Neuroscience Program (CPAD, CPP, CP-RND, CPTA, D-RSC, HD-RSC) is pleased to host the 2022 C-Path Neuroscience Annua